Cardinal Health Signs Exclusive Agreement With HemCon Medical Technologies, Inc. to Distribute Hemorrhage Control Bandages in U.S.

Used for years by U.S. military to control bleeding, HemCon(R) Bandages now

available to U.S. health-care professionals as a new weapon to save lives,

fight uncontrolled hemorrhage

Jul 19, 2007, 01:00 ET from Cardinal Health Inc.

    DUBLIN, Ohio, July 19 /PRNewswire-FirstCall/ -- Cardinal Health, a
 global provider of products and services that improve the safety and
 productivity of health care, today announced an exclusive, four-year
 distribution agreement with HemCon Medical Technologies, Inc. to provide
 its new line of hemorrhage control bandages to hospitals, surgery centers
 and physician offices in the United States.
     HemCon(R) Bandages, used by the U.S. military since 2003, have
 demonstrated a 97% effective rate in controlling bleeding on the
 battlefield (1). HemCon recently reengineered its bandages to meet the
 specific needs of civilian trauma and emergency medicine. The new bandages,
 which control severe arterial bleeding, are thinner, more flexible and
 sized differently than the original HemCon military bandage. The technology
 used in the bandages is particularly useful in hospital settings, because
 it allows providers to standardize one hemorrhage control solution across
 multiple disciplines.
     "The U.S. military has used our bandages to save soldiers' lives for
 years, so we're excited to now form this exclusive partnership with
 Cardinal Health to bring this life-saving technology to the United States
 civilian sector as well," said John W. Morgan, president and CEO of HemCon
 Medical Technologies, Inc. "Cardinal Health's extensive clinical expertise
 and strong hospital relationships made it the ideal partner to bring
 HemCon's innovative technology to the U.S. health-care market. This
 partnership will allow a higher standard of care that will benefit both
 clinicians and patients."
     Using Chitosan, an extract from shrimp shells, the HemCon(R) Bandage
 controls moderate to severe external bleeding within minutes of being
 applied directly to moderate- or high-pressure, high-flow external bleeds.
 It aggressively adheres to the site when it contacts blood or moisture.
 This adhesive-like action forms a strong, flexible barrier that seals and
 stabilizes the wound.
     "Uncontrolled bleeding is the second leading cause of death in the
 United States, after trauma (2), and more than six million bleeding wounds
 are treated annually by trauma and emergency rooms in the U.S. (3)," said
 Mike Kaufmann, president of Healthcare Supply Chain Services-Medical for
 Cardinal Health. "That's just one reason why we are thrilled to have the
 exclusive opportunity to bring this life-saving product to health-care
 providers throughout the United States. This partnership is a perfect
 example of Cardinal Health's commitment to delivering innovative products
 that improve patient outcomes."
     By directly controlling blood loss, even in the case of severed
 arterial bleeds, HemCon(R) Bandages reduce the need for transfusions and
 provide critical time to administer care (up to 48 hours from the point of
     HemCon's new bandages are available in a variety of sizes, have a
 three- year shelf life and are latex-free. These sizes were chosen to
 specifically address the wounds seen in civilian emergency and trauma cases
 such as lacerations, knife injuries, motor vehicle accidents and gunshot
 wounds. In addition to being useful in the emergency room, HemCon Bandages
 are also useful in cardiac catheterization and interventional radiology
     The products will be co-labeled by HemCon and Cardinal Health, and will
 be available through Cardinal Health hospital supply distribution and in
 Presource(R) kits and trays. For product information, Cardinal Health
 customers should contact their hospital supply sales representative.
 Information is also available by calling Cardinal Health at 847-689-6459.
     About HemCon Medical Technologies, Inc.
     HemCon Medical Technologies Inc., founded in 2001, develops,
 manufactures, and markets innovative technologies to control bleeding and
 infection resulting from trauma or surgery. HemCon products are designed
 for use by military and civilian first responders as well as medical
 professionals in hospital, dental and clinical settings where rapid control
 of bleeding is of critical importance. HemCon's manufacturing and corporate
 headquarters are located in Portland, Oregon. To learn more, visit
     About Cardinal Health
     Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE:   CAH) is an
 $80 billion, global company serving the health-care industry with products
 and services that help hospitals, physician offices and pharmacies reduce
 costs, improve safety, productivity and profitability, and deliver better
 care to patients. With a focus on making supply chains more efficient,
 reducing hospital-acquired infections and breaking the cycle of harmful
 medication errors, Cardinal Health develops market-leading technologies,
 including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems,
 MedMined(R) data mining software and the CareFusion(TM) patient
 identification system. The company also manufactures medical and surgical
 products and is one of the largest distributors of pharmaceuticals and
 medical supplies worldwide. Ranked No. 19 on the Fortune 500 and No. 1 in
 its sector on Fortune's ranking of Most Admired firms, Cardinal Health
 employs more than 40,000 people on five continents. More information about
 the company may be found at
     Except for historical information, all other information in this news
 release consists of forward-looking statements within the meaning of the
 Private Securities Litigation Reform Act of 1995, as amended. These
 forward- looking statements are subject to risks and uncertainties that
 could cause actual results to differ materially from those projected,
 anticipated or implied. The most significant of these uncertainties are
 described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports
 (including all amendments to those reports) and exhibits to those reports,
 and include (but are not limited to) the following: competitive pressures
 in its various lines of business; the loss of one or more key customer or
 supplier relationships or changes to the terms of those relationships;
 changes in the distribution patterns or reimbursement rates for health-care
 products and/or services; the results, consequences, effects or timing of
 any inquiry or investigation by any regulatory authority or any legal and
 administrative proceedings; difficulties, delays or additional costs in
 implementing the company's global restructuring program; and general
 economic and market conditions. Except to the extent required by applicable
 law, Cardinal Health undertakes no obligation to update or revise any
 forward-looking statement.
     (1) Wedmore, Ian, John G. McManus, Anthony E. Pusateri, and John B.
 Holcomb. "A Special Report on the Chitosan-based Hemostatic Dressing:
 Experience in Current Combat Operations." Journal of Trauma: Injury,
 Infection and Critical Care 60.3 (2006) : 655 - 658.
     (2) Sauaia, A., Moore, F. A., Moore, E. E., et al. (1995). Epidemiology
 of trauma deaths: a reassessment. J Trauma, 38,185-193.
     (3) National Hospital Ambulatory Medical Care Survey: 2004 Emergency
 Department Summary, Centers for Disease Control, 2004 Report.

SOURCE Cardinal Health Inc.